# Analysis: WAT_2025_Q2.txt

*Model: gpt-3.5-turbo*

---

### 1. Quarter & Company Context
- **Company:** Waters Corporation (WAT)
- **Quarter/Year:** Second quarter of 2025
- **Key Context:** Strong execution, innovation, and expansion into higher growth areas drove sales growth of 9% reported and 8% constant currency. Strategic pillars include commercial execution, innovation, and growth accretion vectors.

### 2. Headline Financial Results
- **Revenue:** $771 million, up 9% reported and 8% constant currency
- **EPS:** Non-GAAP EPS of $2.95, up 12% YoY
- **Margins:** Gross margin at 58.3%, adjusted operating margin at 29.1%
- **Guidance:** Raised full-year 2025 constant currency sales growth to 5.5%-7.5% and non-GAAP EPS to $12.95-$13.05

### 3. Management Commentary
- **Strategic Initiatives:** Strong commercial execution, revitalized innovation, and expansion into high-growth adjacencies.
- **Product Launches:** Alliance IS, Zivo TQ Absolute, BioResolve Protein A columns, and Empower enhancements.
- **Market Updates:** GLP and PFAS testing revenue growth, India revenue growth, and price contribution.

### 4. Q&A Highlights
- **Analyst Questions:** Focus on LCMS growth drivers, margin performance, China market dynamics, and synergy plans post-acquisition.
- **Management Responses:** Confident in strong replacement cycle, robust funnel activity, and conservative assumptions for China growth.

### 5. Market/Investor Sentiment Signals
- **Forward-Looking Commentary:** Continued momentum in core business, synergies post-acquisition, and growth opportunities in biosciences and diagnostics.
- **Surprises:** Strong LCMS growth, margin impact from tariffs, and conservative guidance despite positive trends.

### 6. Takeaways
- **Positive:** Strong sales growth, successful strategic pillars execution, and raised guidance.
- **Negative:** Impact of tariffs on margins, conservative approach to China growth.
- **Uncertainties:** Synergy realization post-acquisition, sustainability of LCMS growth, and academic/government funding trends.

### 7. Other Notable Information
- **Legal/Regulatory:** Cautionary language on forward-looking statements, non-GAAP financial measures, and risk factors.
- **M&A:** Pending combination with BD Biosciences and Diagnostic Solutions business, expected financial and operational impact.
- **Leadership:** Integration leadership announced, Chris Ross to lead the Integration Office post-acquisition.